Skip to main content
    N

    NeoGenomics Inc (NEO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $16.02
    -0.52 (-3.14%)

    Market Cap: $2.07B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    NeoGenomics Inc (NEO) Financials: Revenue, Profit and Cash Flow

    Updated Oct 28, 2026. Financial statements from company filings, amounts in US dollars.

    NeoGenomics reported revenue of $727.33M for the fiscal year ended Dec 31, 2025, up 10.1% from the year before. That year, net income was -$108.03M with a net margin of -14.9%, operating cash flow was $5.23M and free cash flow was -$21.78M. The quarter ended Sep 30, 2026 had revenue of $209.25M and net income of -$7.55M.

    Revenue and Margins

    The operating margin was -9.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $244.08M, a compound annual rate of 12.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$727.33M+10.1%38.8%-9.1%-14.9%
    Dec 2024$660.57M+11.6%43.9%-13.9%-11.9%
    Dec 2023$591.64M+16.1%41.3%-18.2%-14.9%
    Dec 2022$509.73M+5.2%36.9%-30.9%-28.3%
    Dec 2021$484.33M+9.0%38.6%-24.5%-1.7%
    Dec 2020$444.45M+8.7%41.8%-3.1%0.9%
    Dec 2019$408.83M+47.7%48.1%3.2%2.0%
    Dec 2018$276.74M+15.2%46.0%3.6%1.0%
    Dec 2017$240.25M-1.6%42.4%1.2%-0.2%
    Dec 2016$244.08MN/A45.2%1.1%-2.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$727.33M$660.57M$591.64M$509.73M$484.33M$444.45M$408.83M$276.74M$240.25M$244.08M
    Cost of revenue$444.79M$370.47M$347.04M$321.83M$297.27M$258.56M$211.99M$149.48M$138.29M$133.70M
    Gross profit$282.54M$290.10M$244.60M$187.90M$187.06M$185.89M$196.84M$127.27M$101.96M$110.38M
    Research and development$37.08M$31.16M$27.31M$30.33M$21.87M$8.23M$8.49M$3.00M$3.64M$4.65M
    Operating income-$66.08M-$92.11M-$107.74M-$157.62M-$118.75M-$13.99M$13.01M$10.04M$2.90M$2.57M
    Net income-$108.03M-$78.73M-$87.97M-$144.25M-$8.35M$4.17M$8.01M$2.64M-$396.00K-$6.14M
    EBITDA-$38.69M-$1.51M-$17.61M-$82.33M$46.50M$28.68M$37.63M$31.79M$26.55M$25.36M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$209.25M$201.66M$186.67M$190.17M$187.80M$181.33M$168.03M$172.00M$167.82M$164.50M$156.24M$155.55M
    Gross profit$96.59M$91.88M$80.86M$75.71M$80.45M$77.26M$73.25M$77.26M$74.88M$72.49M$65.47M$67.59M
    Operating income-$7.94M-$9.77M-$18.24M-$11.14M-$27.01M-$47.63M-$27.82M-$18.40M-$21.20M-$21.94M-$30.57M-$18.57M
    Net income-$7.55M$2.24M-$17.11M-$9.88M-$27.13M-$45.09M-$25.92M-$15.32M-$17.70M-$18.64M-$27.06M-$14.33M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $346.63M exceeded cash and equivalents by $187.02M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.36B$1.64B$1.68B$1.74B$1.87B$988.33M$709.51M$505.01M$343.34M$337.12M
    Current assets$376.29M$596.02M$596.81M$605.29M$681.51M$448.73M$290.74M$103.67M$84.96M$78.83M
    Cash and equivalents$159.62M$367.01M$342.49M$263.18M$316.83M$228.71M$173.02M$9.81M$12.82M$12.53M
    Total liabilities$523.27M$735.70M$739.69M$742.01M$761.50M$294.04M$202.10M$184.57M$137.81M$150.52M
    Short-term debt$4.78M$204.16M$5.61M$6.65M$9.15M$7.81M$13.81M$20.47M$8.99M$30.53M
    Long-term debt$341.86M$340.33M$538.20M$535.32M$532.48M$168.12M$91.83M$92.88M$91.13M$91.95M
    Shareholder equity$836.56M$902.34M$941.54M$998.02M$1.11B$694.29M$507.41M$320.44M$205.53M$186.60M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.38B$1.35B$1.35B$1.36B$1.37B$1.39B$1.60B$1.64B$1.64B$1.64B$1.64B$1.68B
    Total liabilities$576.28M$565.65M$517.77M$523.27M$536.49M$539.91M$713.16M$735.70M$732.90M$727.39M$716.93M$739.69M
    Cash and equivalents$139.28M$145.54M$146.14M$159.62M$164.12M$154.72M$346.19M$367.01M$361.99M$355.08M$331.91M$342.49M
    Shareholder equity$800.64M$785.73M$828.76M$836.56M$838.29M$854.04M$888.27M$902.34M$908.21M$915.88M$923.41M$941.54M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$5.23M$7.02M-$1.95M-$65.99M-$26.72M$1.46M$23.37M$44.79M$18.04M$21.48M
    Capital expenditures$27.01M$41.06M$28.75M$30.89M$64.14M$29.10M$20.03M$14.31M$13.69M$7.54M
    Free cash flow-$21.78M-$34.04M-$30.70M-$96.88M-$90.86M-$27.64M$3.34M$30.48M$4.35M$13.94M
    Dividends paidN/AN/AN/AN/AN/AN/AN/A$9.60M$0$87.86M
    Investing cash flow-$12.34M$12.86M$76.71M$517.00K-$632.37M-$159.44M-$19.63M-$139.69M-$13.69M-$6.50M
    Financing cash flow-$200.29M$4.65M$4.55M$11.83M$725.28M$235.60M$159.47M$91.96M-$4.09M-$25.87M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$8.88M$19.96M-$8.14M$1.34M$8.88M$20.33M-$25.33M$9.80M$9.25M$13.89M-$25.91M$17.78M
    Capital expenditures$11.77M$8.22M$5.00M$7.87M$8.31M$6.32M$4.50M$11.60M$10.80M$13.08M$5.58M$7.06M
    Free cash flow-$20.66M$11.74M-$13.14M-$6.53M$570.00K$14.01M-$29.83M-$1.80M-$1.55M$814.00K-$31.50M$10.73M
    Last 12 quarters

    Frequently Asked Questions About NEO

    What is NeoGenomics' annual revenue?

    NeoGenomics reported revenue of $727.33M for the fiscal year ended Dec 31, 2025.

    How fast is NeoGenomics' revenue growing?

    Revenue was up 10.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 12.6%.

    Is NeoGenomics profitable?

    No. NeoGenomics reported net income of -$108.03M for the fiscal year ended Dec 31, 2025, with a net margin of -14.9%.

    How much free cash flow does NEO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $5.23M minus capital expenditures of $27.01M produced free cash flow of -$21.78M.

    How much debt does NeoGenomics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $341.86M, short-term debt of $4.78M and cash and equivalents of $159.62M.